The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancerenglish
To make recommendations in the maintenance setting regarding the use of systemic treatment in the care of patients with non-small cell lung cancer (NSCLC).
Advanced, stage IIIB/IV patients who have NSCLC who have not progressed (i.e., complete response, partial response or stable disease) following four to six cycles of platinum-based chemotherapy and maintained an Eastern Cooperative Oncology Group performance status of 0 to 2.
Intended Guideline Users
Oncologists involved in the care of patients with NSCLC who require maintenance systemic treatment.
- In patients with advanced NSCLC who have received initial first-line platinum-based chemotherapy for a minimum of four cycles, does maintenance systemic therapy improve overall survival (OS), progression-free survival (PFS), or quality of life in comparison with either placebo or second line therapy at the time of progression?
- In patients with advanced NSCLC who have received initial first-line platinum-based chemotherapy for a minimum of four cycles, does any systemic therapy agent improve OS, PFS or quality of life in comparison with other systemic therapies?
- In patients with advanced NSCLC, are there any clinical or molecular characteristics that identify subgroups of patients who derive greater benefit from maintenance systemic therapy?